Abstract

Pulmonary fibrosis (PF) is a chronic and progressive pulmonary interstitial disease of unknown etiology and is also a sequela in severe patients with the Coronavirus Disease 2019 (COVID-19). Seven databases were systematically searched to evaluate the preclinical evidence of Tanshinone IIA (Tan IIA) on PF. The quality of the included studies was assessed using a 10-item risk of bias tool, and data were analyzed using RevMan 5.3 software. 22 experiments from 12 studies on a total of 248 animals were included. The results showed that PF phenotype, such as fibrotic score, collagen I (Col-I), collagen III (Col-III), hydroxyproline (Hyp), in the group treated with Tan IIA were significantly lower than those in the model group (p < 0.00001). The potential mechanisms of Tan IIA improvement of PF involve reducing inflammation, antioxidation, and suppressing activation of transforming growth factor beta 1 (TGF-β1). The subgroup analysis of different models, different rat species, and different dosage time showed significant reduction in fibrotic scores and Hyp levels with Tan IIA. The preclinical evidence indicated that Tan IIA might be a potent and promising agent for PF, but this conclusion should be further confirmed with more research.

Author Details

Authors

• Li-ying Peng¹
• Jun-jun Shi¹
• Yue Liang¹
• Yang Li¹
• Yan Tang¹
• Tuo Kai¹
• Andong Yang¹
• Zi-yue Xiong²

Departments

• ¹ Center of Instrumental Analysis, Sichuan Academy of Chinese Medicine Sciences, and
• ² The Third People’s Hospital of Chengdu, Chengdu, Sichuan, China

Address

Zi-yue Xiong, Pharmacist
The Third People’s Hospital of Chengdu
82th Street Qinglong
Chengdu 610031, Sichuan, People’s Republic of China
Email: [email protected]

Citation